Harrow
Joel Wilde has over 17 years of experience in the sales and business development field. Joel most recently worked as the Central Area Sales Director at Harrow since June 2022. Prior to that, they served as the Ophthalmics National Director - Strategic Accounts at AIS Healthcare from July 2020 to June 2022. Before that, they worked as a Sales Representative at Precision Lens from July 2017 to 2020. Joel also held positions as Regional Business Director at Imprimis Pharmaceuticals, Inc. from October 2015 to July 2017, Ophthalmic Specialty Representative at Bausch + Lomb from June 2014 to October 2015, Business Development Representative at Essilor Laboratories from October 2013 to June 2014, Senior Territory Manager at Inspire from July 2006 to October 2013, and Eye Care Representative at CIBA Vision from November 2004 to July 2006.
Joel Wilde attended the University of Wisconsin-Green Bay, but no specific information about their degree or field of study is available.
This person is not in any offices
Harrow
2 followers
Harrow (Nasdaq: HROW) is a leading U.S. eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic prescription therapies that are accessible and affordable. Harrow owns U.S. commercial rights to ten FDA-approved ophthalmic pharmaceutical products. Harrow also owns and operates ImprimisRx, the leading U.S. ophthalmic‑focused pharmaceutical compounding business, which also serves as a mail-order pharmacy licensed to ship prescription medications in all 50 states. Harrow has non-controlling equity positions in Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc., companies that began as subsidiaries of Harrow. Harrow also owns royalty rights in four late-stage drug candidates being developed by Surface and Melt.